在治疗侵蚀性食道炎时,评估用诺普拉赞替代兰索普拉的成本效益
Saeash Jeyarajan1, Thejasvin K2, Sneha Pimpalnerkar3
1Business School, Imperial College London, London, UK.
BMJ open gastroenterology
|May 12, 2025
概括
诺普拉赞在治疗严重侵蚀性食道炎方面显示出潜在的成本效益,特别是在考虑愈合率和质量调整后生命年 (QALYs) 时. 需要进一步的研究来优化其用于更广泛的患者群体的使用和剂量.
科学领域:
- 胃肠病学 胃肠病学
- 卫生经济学 卫生经济学
背景情况:
- 侵蚀性食道炎的管理通常涉及质子抑制剂 (PPI).
- 沃诺普拉赞提供了一种新的治疗方法.
- 与标准的个人消毒剂相比,诺普拉桑的成本效益需要进行彻底的经济评估.
研究的目的:
- 进行vonoprazan与lansoprazole用于侵蚀性食道炎的成本效益分析.
- 根据临床试验数据,评估诺普拉赞治疗的经济影响.
主要方法:
- 经济评估使用来自双盲随机对照试验的数据.
- 成本以英 (£) 表示.
- 通过32周的疾病解消来评估有效性,并使用质量调整后生命年 (QALYs) 进行二次分析.
主要成果:
- 主要增量成本效益比 (ICER) 每个决议为3421.27英.
- 每个QALY的ICER略高于NICE的值 (34,747.32英).
- 小组分析表明严重食道炎的成本效益 (ICER/QALY £22,165.56) 和非侵入性解决评估 (£15,826.98).
- 敏感性分析强调了严重病例的潜在成本效益,但建议对vonoprazan的剂量和持续时间进行指导方针优化.
结论:
- 诺普拉桑在严重侵蚀性食道炎的初始治愈中具有潜在的成本效益.
- 需要进一步的试验来确定基于症状的处方的成本效益.
- 诺普拉桑的最佳剂量,频率和持续时间需要进一步的经济评估.
相关概念视频
Peptic Ulcer Disease IV: Management
55
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
55
Gastroesophageal Reflux Disease II: Clinical Features and Management
42
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
42
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
320
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
320
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
378
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
378
Peptic Ulcer Disease V: Surgical Management and Nursing Care
179
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
179
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
342
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
342


